Research progress through September 24, 2026
21 companies followed. One clinical setback documented since admission.
We evaluate companies with the 25-Gate Framework, preserve the dated assessment, then follow the evidence.
| Research list | Documented clinical setbacks |
|---|---|
| Tracker | 0 of 11 · 0% |
| Scout | 1 of 10 · 10% |
| Overall | 1 of 21 · 4.8% |
Five companies have documented clinical or regulatory progress. For the other 15, no qualifying milestone or clinical setback has been verified in this record.
The setback was Longeveron’s missed primary trial endpoint. The five progress cases are Repair, Cyclarity, ProKidney and BioAge in Tracker, and Serina in Scout.
Not a success rate or investment return. These counts describe the events verified in this record, not a complete audit of every company development. No documented setback does not mean success or low risk. Follow-up periods differ, and outcomes are still developing.
One framework. Two research lists.
Tracker: a stronger overall research case at admission.
Scout: a company worth following, with more unresolved questions.
The framework examines the mechanism, human evidence, valuation, financing and other company risks. Historical scores overlap between the lists because framework versions and admission conditions differ. A score alone does not determine the list.
Learn to evaluate longevity biotech companies better.
Learn how longevity treatments work and meet the companies developing them. Get a free weekly mechanism lesson and a company overview, in plain English.
No biotech background needed.
What happened after we added each company?
Open a company to see its recorded score and follow-up. Oldest admissions appear first within each list. Scores are historical, not current recommendations.
Recorded score: 3.19 · earlier framework.
Progress: May 12: REP-0003 received FDA RDEP eligibility for homozygous familial hypercholesterolemia. A step in the regulatory process, not approval or evidence of patient benefit. Source.
What to watch: Human testing, safety and evidence of benefit. Eric holds equity in this company.
Recorded score: 3.48 · earlier framework.
Progress: May 14: reported Phase 1 removal of 7-ketocholesterol in urine, consistent with the intended mechanism. This does not establish plaque regression or clinical benefit. Source.
What to watch: Controlled evidence of plaque changes, safety and patient benefit.
Recorded score: 2.94 · earlier framework.
Progress: No post-admission clinical or regulatory milestone has been verified in this record. This is not a finding that the company has made no progress.
What to watch: New human evidence and safety data.
Recorded score: 3.32 · earlier framework.
Progress: Correction: the preliminary skin-study findings were announced May 28, before admission, rather than June 15 as previously recorded. They are excluded from the post-admission milestone count. A planned study is not a completed clinical milestone. Source.
What to watch: New controlled patient results, durability and safety.
Recorded score: 4.18.
Progress: The company announced acceptance of first-human ISM6331 data for an October ESMO presentation. Acceptance and a preclinical candidate nomination are not counted as completed clinical or regulatory milestones in this summary. Source.
What to watch: Actual patient findings, safety and durability.
Recorded score: 3.68 · earlier framework.
Progress: September 15: announced additions to its clinical advisory and leadership teams. These appointments are not a clinical or regulatory milestone. The Parkinson’s trial announcement in March preceded admission. Source.
What to watch: Controlled clinical results and safety.
Recorded score: 3.70 · earlier framework.
Progress: No post-admission clinical or regulatory milestone has been verified in this record. This does not mean the company is inactive. Source.
What to watch: Human safety, kidney-function evidence and trial execution.
Recorded score: 3.55 · earlier framework.
Progress: No post-admission clinical or regulatory milestone has been verified in this record.
What to watch: New patient data, safety and development milestones.
Recorded score: 3.73 · earlier framework.
Progress: No post-admission clinical or regulatory milestone has been verified in this record.
What to watch: Human kidney-function evidence, safety and financing.
Recorded score: 3.92 · August 2 rescore, not entry score.
Progress: August 10: reported enrollment completion for approximately 320 participants contributing to the PROACT 1 efficacy analysis. Enrollment is execution progress, not proof that the treatment works. Source.
What to watch: Pivotal results expected in Q2 2027, plus financing through the readout.
Recorded score: 3.91 · August 2 audit, not original Scout score.
Progress: September 8: reported the first participant dosed in Phase 2 QUELL-DME and completion of QUELL-CV enrollment. These steps do not establish treatment efficacy. Source.
What to watch: Controlled efficacy and safety results. Counted once, in Tracker.
Recorded score: 3.59.
Progress: September 16: ELPIS II missed its primary efficacy endpoint. The company announced a strategic review and cash-conservation plans. An earlier financing-risk warning did not predict this trial result. Source.
What to watch: Full data, FDA feedback, revised development plans and financing. Historical score is not a current endorsement.
Recorded score: 3.73.
Progress: No post-admission clinical or regulatory milestone has been verified in this record. The January FDA authorization predates admission. Source.
What to watch: Initial human safety and durable vision outcomes.
Recorded score: 3.91.
Progress: No post-admission clinical or regulatory milestone has been verified in this record.
What to watch: Safety and meaningful liver-function improvement; verified terms and access.
Recorded score: 3.68.
Progress: September 9: an independent blinded safety review supported advancing SER-252 to cohort 2. Early dosing progress and exploratory observations do not establish treatment benefit. Source.
What to watch: Patient safety, durability, Parkinson’s OFF-time results and financing.
Recorded score: 3.79.
Progress: No post-admission clinical or regulatory milestone has been verified in this record.
What to watch: Controlled evidence of muscle preservation during immobilization, plus safety.
Recorded score: 3.53.
Progress: No post-admission clinical or regulatory milestone has been verified in this record.
What to watch: Complete first-human safety and exposure data, and a clear patient-study plan.
Recorded score: 3.96.
Progress: No post-admission clinical or regulatory milestone has been verified in this record.
What to watch: Lead-subsidiary human results, ownership economics and investor rights.
Recorded score: 3.52.
Progress: No post-admission clinical or regulatory milestone has been verified in this record.
What to watch: Controlled, durable improvements in strength or walking, and a reconciled study record.
Recorded score: 3.50 at entry; 3.34 on August 22.
Progress: September 8: disclosed a May 5 FDA QIDP designation. Because the designation predates admission, it is excluded from the post-admission count. QIDP is not approval or proof of efficacy. Source.
What to watch: A registered human study, applicable clearance, dosing and safety data.
Recorded score: 3.90 · hypothetical-access scenario.
Progress: No post-admission clinical or regulatory milestone has been verified in this record. Admission used a hypothetical-access scenario, not verified availability of an investment.
What to watch: Full pig-kidney preservation data, a regulator-aligned human-organ plan, verified rights and access.
Cutoff: September 24, 2026. The denominator includes all 21 permanent names in this record, including the Scout setback and companies without a verified update. BioAge is counted once in Tracker following its August 2 promotion; progress is measured from first permanent admission. Watchlist names and retrospective backtests are excluded.
Qualifying milestones: an actual clinical execution step, reported human target-engagement evidence, or a regulatory development step dated after admission. The four Tracker names counted are Repair, Cyclarity, ProKidney and BioAge; the Scout name is Serina. Planned trials, presentation acceptance, preclinical nominations, appointments, financing announcements and events before admission are not counted. Percentages are rounded.
Limits: this is a count of linked, verified events in this record, not an exhaustive audit of every development. Follow-up periods differ and the groups are small. Company announcements are not independent validation. Milestones can coexist with serious risks or later failures. This record does not establish that the framework predicts outcomes or outperforms another method.
Historical scores: preserved from EverLife’s prior record, without new rescoring. ProKidney’s 3.92 and BioAge’s 3.91 are dated August 2 reassessments; original entry scores were not available in the record reviewed. Maxwell’s original 3.50 and subsequent 3.34 both remain visible.
September 24 correction: Rubedo’s preliminary skin-study release was May 28, before its June 3 admission. The earlier June 15 attribution was incorrect. This update replaces the older milestone summary with the defined counts above. Original records remain backed up. No stock-price gains, losses or estimated private valuations are used to imply results.
Backtests: UNITY Biotechnology was scored only after its failure was known. Its retrospective 3.30 score is excluded from these counts.
Conflicts: Eric Pemper holds personal equity in Repair Biotechnologies and Yuva Biosciences. Those holdings may create bias. EverLife has not received cash, stock or other compensation from the companies discussed here; any change will be disclosed with the relevant coverage.
Educational, impersonal research only. Not investment or medical advice. Classifications are not recommendations, price targets or assurances of suitability or access. No clinical outcome, lifespan benefit or financial return is guaranteed. Full disclosure.